Pulling SEC filings + quote and writing the call…

Chiron Real Estate Inc.
Next earnings Aug 3, 2026 (after close) · consensus $-0.09 EPS, $40.7M rev
Last earnings +0.7% on 2026-05-06
Beaten-down single-tenant healthcare REIT at ~1x book with covered cash flow, but rising rates and impairments are eroding earnings.
Operating cash flow $73.6M · FY2025
Read as a REIT rather than an operating company, XRN's headline FY2025 net loss of -$6.88M is misleading. The MD&A shows the loss is driven almost entirely by non-cash charges: $44.0M depreciation, $15.0M amortization, and $13.0M of property impairments (two properties in Aurora, IL and Melbourne, FL written down to contractual sale prices). Strip those out and the business still generated $73.6M of operating cash flow (+5.1% YoY) on rental revenue of $147.7M (+6.8%). Approximate FFO (net loss + D&A + impairments ≈ $65M, ~$4.9/share) puts the stock near ~7-8x FFO and roughly 0.98x book (equity $510M vs. $503M market cap) — an undemanding valuation for a real-estate portfolio still carried at $1.2B.
That cheapness is the reason not to sell, but the deterioration is the reason not to buy. Net income has fallen every year since FY2023 ($21.7M → $6.69M → -$6.88M), and the culprits are structural, not one-off. Interest expense rose to $31.8M as market rates climbed on what the 10-K flags as 'unhedged floating-rate debt' from the Credit Facility; the company is directly exposed if rates stay high. Impairments are also becoming a pattern ($1.7M in 2024, then $13.0M in 2025) as the REIT sells assets below carrying value, hinting the $1.2B book may still be optimistic in places. Management did extend weighted-average debt term to 4.1 years (from 2.0) at a 3.74% rate — a genuine positive that de-risks near-term maturities.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 3, 2026, 12:41 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $116M | $137M | $141M | $139M | $148M |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $18.3M | $20.0M | $21.7M | $6.69M | -$6.88M |
| Diluted EPS | $0.19 | $0.20 | $1.13 | $0.06 | -$0.91 |
| Net margin | 15.8% | 14.6% | 15.4% | 4.8% | -4.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Closed an asset acquisition/disposition under a new material agreement
Filed shelf registration — capacity for future stock/debt sales, dilution overhang
Recap: new debt, unregistered stock sale, charter amendment, holder rights modified
Annual meeting vote results plus a board/officer change and Reg FD update
New material agreement with unregistered stock issuance — potential dilution
Q1 2026 report; REIT working through impairments and higher rate costs
Released Q1 results alongside a new material agreement and other disclosures
Proxy for annual meeting: director elections and executive-pay vote
Entered a material agreement and amended charter/bylaws
Sources: SEC EDGAR (CIK 0001533615, latest 10-Q filed 2026-05-07) · EODHD · Proprietary analysis · as of 7/3/2026, 4:41:30 AM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 5 open-market buys · 0 sales
| 2026-05-14 | Cypher Matthew Director | Buy | 1.42K @ $35.12 | $49.9K |
| 2026-05-12 | Wittman Lori Director | Buy | 2.94K @ $33.85 | $99.5K |
| 2026-05-12 | Marston Ronald Director | Buy | 189.00 @ $34.05 | $6.43K |
| 2026-05-12 | Marston Ronald Director | Buy | 1.01K @ $34.06 | $34.4K |
| 2026-05-12 | Marston Ronald Director | Buy | 300.00 @ $34.14 | $10.2K |
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
1195 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.